Xcellerant Ventures

What Xcellerant Ventures does

Xcellerant Ventures is a Scottsdale/Phoenix, Arizona-based venture capital firm founded in 2023 that invests in early-stage HealthTech, MedTech, and BioTech companies. The firm deploys capital through two vehicles: XVC Fund 1 for direct portfolio investments and the Jetstream Venture Fund, an SEC-declared effective interval fund launched in October 2025 in partnership with Sweater Industries LLC that provides VC-style exposure with a $5,000 minimum investment (lowered from $20,000 in March 2026), semi-annual liquidity, an evergreen structure, and a flat 2.9% management fee with no carried interest. Jetstream's distribution targets individual professional investors historically shut out of institutional-quality VC.

The firm's 10+ portfolio companies are concentrated in revenue-generating, FDA-cleared or regulatory-pathway-clear businesses. Notable holdings include DeepLook Medical (FDA-cleared DL Precise AI tumor segmentation, with deployments at Banner MD Anderson and an Oxford NHS clinical study), AdviNOW Medical (AI/AR clinical automation with 26 pending patents), CRISPR QC (CRISPR Analytics Platform, $10M Series A led by Xcellerant), Lenoss Medical (OsteoPearl biological allograft with 23 granted patents), Mindset Medical (contactless vital sign monitoring via ASU-licensed rPPG), and Mu Medical (precision ophthalmology consolidating Nanodropper, Bedo Solutions, and Viseon Labs). The firm has also extended into adjacent verticals through Jetstream secondary investments in SpaceX and Carbogenesis, and into AI pharma research via Hill Research.

Xcellerant is led by founders John Shufeldt (MD, JD, MBA), Douglas Sylvester (former ASU Law Dean), and Chris Yoo (PhD), supported by General Partner Michael Shufeldt and approximately eight additional team members. The firm's investment edge is anchored in the partners' seven decades of combined healthcare, legal, and entrepreneurial experience and a track record of exits including MeMD (acquired by Walmart, 10x MOIC), NextCare Urgent Care ($100M revenue, PE sale), StatRead (50x MOIC), and Systems Imagination (100x MOIC). Revenue is generated primarily through management fees on fund AUM and future carried interest, though firm-level revenue is not publicly disclosed.

Name

Xcellerant Ventures

Legal name

Xcellerant Ventures

Website

https://xcellerantventures.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Xcellerant Ventures is a Phoenix-based early-stage venture capital firm founded in 2023 that invests in HealthTech, MedTech, and BioTech startups through XVC Fund 1 and the SEC-registered Jetstream interval fund, targeting founders with FDA-cleared or revenue-generating healthcare innovations.

Ownership category

akta.pro rank

Product category

Venture Capital / Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Vehicles (52599)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Multi-Sector / Generalist Growth Equity (FSANACAO)

Keywords

• Venture capital funding
• Healthcare investment
• Early stage investing
• Venture fund management
• Medtech investment

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Management Fees: Jetstream Venture Fund charges a flat 2.9% management fee plus operating expenses. Uses European waterfall structure returning 100% of invested capital prior to calculating carry.
2. Carried Interest: Traditional VC carried interest profit sharing after returning invested capital to LPs.
3. Portfolio Company Returns: Returns from successful portfolio company exits including acquisitions and IPOs. Notable exits include NextCare Urgent Care (sold to PE), MeMD (acquired by Walmart 2021), StatRead (50x MOIC), Systems Imagination (100x MOIC).

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Xcellerant Ventures is a Phoenix-based venture capital firm that invests in early-stage healthtech and medtech companies. It manages Xcellerant Ventures Fund 1 for traditional LP commitments and the Jetstream Venture Fund, an SEC-declared effective interval fund that democratizes access to venture-style investments with minimums as low as $5,000. The firm also provides hands-on operational, regulatory, and commercialization support to portfolio company founders.

Product overview

Xcellerant Ventures operates as a venture capital firm offering two primary fund products: Xcellerant Ventures Fund 1 for early-stage healthtech and medtech investments, and Jetstream Venture Fund (launched October 2025), an SEC-declared effective interval fund that democratizes access to venture-style investing with a $20,000 minimum and no carried interest. The firm also supports portfolio companies including AdviNOW Medical (AI/AR healthcare automation), DeepLook Medical (DL Precise AI imaging), and Mu Medical (precision eyecare). The firm maintains a podcast (Entrepreneur Rx) and focuses on companies with FDA approvals and expedited paths to growth.

Differentiator

Problem solved

Functional benefit

Brands

• Jetstream Venture Fund: An interval fund managed by Xcellerant Ventures offering access to early-stage venture capital investments with lower minimums ($20,000) and flexible withdrawal options.

Products and services

• Xcellerant Ventures Fund 1
• Jetstream Venture Fund

Quantifiable outcome

• First-time fund managers with aligned GP experience outperform established funds in healthcare sector
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature2 records

Partnerships

Nine partnerships are on record, tiered core and flagship.

• IkonopediacoreChannel Partner/ Reseller/ Distributor · 26 November 2025DeepLook Medical embeds visuals, measurements, and radiomics data into Ikonopedia's reporting platform. Clinicians access DL Precise insights seamlessly within workflow.
• InceptocoreChannel Partner/ Reseller/ Distributor · 26 November 2025DeepLook Medical joins Incepto's medical imaging ecosystem as featured product, serving healthcare organizations including Siemens and enabling hospitals to integrate visualization tools.
• Pintail Strategic AdvisorscoreChannel Partner/ Reseller/ Distributor · 26 November 2025Pintail distributes DeepLook's DL Precise to national network of imaging customers across Mammography, breast MRI, CAD, and workflow areas.
• TestDynamicscoreTechnology or Integration · 26 November 2025DeepLook utilizes TestDynamics' AI imaging platform Satori, consolidating DL Precise AI insights for radiologists in customizable clinical workflow.
• Arizona State UniversityflagshipStrategic or Co-development Partner · 27 October 2025Establishment of the John Shufeldt School of Medicine and Medical Engineering at ASU, integrating medicine, engineering, and entrepreneurship with MD and Master of Science degrees, partnering with local healthcare institutions.
• Oxford University Hospitals NHS Foundation TrustcoreStrategic or Co-development Partner · 27 October 2025DeepLook Medical partnership with Oxford NHS Hospitals for PRECISION-DTI clinical study on dense breast cancer detection using DL Precise technology across 400 patient cases.
• Banner MD AndersoncoreStrategic or Co-development PartnerDeepLook Medical's FDA-cleared DL Precise software deployed at Banner MD Anderson, which serves as lead researcher for upcoming breast surgery trials. DeepLook relocated to Arizona with backing from Xcellerant Ventures.
• Mayo Clinic AcceleratorcoreStrategic or Co-development PartnerAdviNOW Medical participated in Mayo Clinic accelerator program (Health Care Accelerator with ASU) providing entrepreneurial curriculum and expert-led ecosystem for startup growth.
• ASU Biodesign Center for Bioelectronics and BiosensorscoreStrategic or Co-development PartnerMindset Medical licensed remote photoplethysmography technology from ASU Professor Nongjian Tao's laboratory. Company participated in ASU-Mayo Clinic Health Care Accelerator program.

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• ARCH Venture Partners: ARCH is an early-stage venture firm that invests primarily in science-driven healthcare, biotech, and technology companies, closely matching Xcellerant's focus on healthtech/medtech founders with cleared regulatory milestones and high growth potential.
• OrbiMed: OrbiMed is a dedicated healthcare-dedicated investment firm spanning venture, growth, and credit across therapeutics, medical devices, and digital health, making it a direct comparable to Xcellerant's healthtech/medtech vertical focus.
• Section32: Section32 is a venture fund focused exclusively on healthcare and technology convergence, investing in early-to-growth-stage companies across digital health, biotech, and medical devices—comparable to Xcellerant's healthcare-only thesis.
• General Catalyst: General Catalyst operates a sizable healthcare-focused practice alongside tech investments, with a strong emphasis on healthtech transformation and a hands-on operating partner model that mirrors Xcellerant's people-first, operationally-supportive approach.
• Khosla Ventures: Khosla Ventures is a technology and science-focused venture firm with substantial healthtech and biotech exposure, investing at early stages with high conviction—comparable to Xcellerant's approach of targeting founders post-FDA clearance with revenue traction.
• Lux Capital: Lux Capital invests in frontier science and technology ventures, with a meaningful healthcare and biotech allocation. Its approach of backing technically deep founder-operators in regulated markets mirrors Xcellerant's emphasis on dynamic, humble founders.
• NEA (New Enterprise Associates): NEA is a large venture firm with a long-standing healthcare and life sciences practice covering healthtech, biotech, and medical devices at seed through growth stages—a broader-scale peer to Xcellerant's healthcare-vertical strategy.
• Bessemer Venture Partners: Bessemer has a dedicated healthcare franchise investing across digital health, biotech, and medical devices, comparable in specialization to Xcellerant, though with substantially greater AUM and longer fund history.

Broad incumbents

• Andreessen Horowitz (a16z Bio/Health): Andreessen Horowitz operates a dedicated Bio/Health fund alongside its broader technology investing, making it a broad-incumbent peer that overlaps with Xcellerant in healthtech and biotech, but across a much larger diversified platform.

Emerging players

• Civilization Ventures: Civilization Ventures is a small, healthcare-focused venture firm investing in early-stage digital health, biotech, and medical devices—a closely comparable emerging player to Xcellerant in size, stage, and vertical focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/xcellerantventures
• Facebookfacebook.com/xcellerantventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xcellerant Ventures